Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343
Closed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342
Self-citationFully Integrated Artificial Pancreas in Type 1 Diabetes
Breton, M., Farret, A., Bruttomesso, D., Anderson, S., Magni, L., Patek, S., Dalla Man, C., Place, J., Demartini, S., Del Favero, S., et al. (2012) · Diabetes · doi:10.2337/db11-1445 · Cited by 315
Davis, E. A., Keating, B., Byrne, G. C., Russell, M., & Jones, T. W. (1997) · Diabetes Care · doi:10.2337/diacare.20.1.22 · Cited by 273
MD-Logic Artificial Pancreas System
Atlas, E., Nimri, R., Miller, S., Grunberg, E. A., & Phillip, M. (2010) · Diabetes Care · doi:10.2337/dc09-1830 · Cited by 266
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Haidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214
Hovorka, R., Elleri, D., Thabit, H., Allen, J. M., Leelarathna, L., El-Khairi, R., Kumareswaran, K., Caldwell, K., Calhoun, P., Kollman, C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2644 · Cited by 214
Self-citationKovatchev, B. P., Renard, E., Cobelli, C., Zisser, H. C., Keith-Hynes, P., Anderson, S. M., Brown, S. A., Chernavvsky, D. R., Breton, M. D., Mize, L. B., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2076 · Cited by 178
Feasibility of Outpatient Fully Integrated Closed-Loop Control
Kovatchev, B. P., Renard, E., Cobelli, C., Zisser, H. C., Keith-Hynes, P., Anderson, S. M., Brown, S. A., Chernavvsky, D. R., Breton, M. D., Farret, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1965 · Cited by 177
Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas
Russell, S. J., El-Khatib, F. H., Nathan, D. M., Magyar, K. L., Jiang, J., & Damiano, E. R. (2012) · Diabetes Care · doi:10.2337/dc12-0071 · Cited by 176
Nimri, R., Muller, I., Atlas, E., Miller, S., Fogel, A., Bratina, N., Kordonouri, O., Battelino, T., Danne, T., & Phillip, M. (2014) · Diabetes Care · doi:10.2337/dc14-0835 · Cited by 169
Thabit, H., Lubina-Solomon, A., Stadler, M., Leelarathna, L., Walkinshaw, E., Pernet, A., Allen, J. M., Iqbal, A., Choudhary, P., Kumareswaran, K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70114-7 · Cited by 151
Self-citationJohnson, S. R., Cooper, M. N., Davis, E. A., & Jones, T. W. (2013) · Diabetic Medicine · doi:10.1111/dme.12247 · Cited by 146
Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R. H., Wadwa, R. P., Wilson, D. M., Ly, T. T., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3053 · Cited by 140
Self-citationLy, T. T., Roy, A., Grosman, B., Shin, J., Campbell, A., Monirabbasi, S., Liang, B., von Eyben, R., Shanmugham, S., Clinton, P. K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3073 · Cited by 135
Leelarathna, L., Dellweg, S., Mader, J. K., Allen, J. M., Benesch, C., Doll, W., Ellmerer, M., Hartnell, S., Heinemann, L., Kojzar, H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2911 · Cited by 133
Self-citationLy, T. T., Breton, M. D., Keith-Hynes, P., DeSalvo, D. J., Clinton, P. K., Benassi, K., Mize, B., Cherñavvsky, D. R., Place, J., Wilson, D. M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0147 · Cited by 125
Haidar, A., Legault, L., Matteau-Pelletier, L., Messier, V., Dallaire, M., Ladouceur, M., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(15)00141-2 · Cited by 115
Artificial Pancreas Project at Cambridge 2013
Hovorka, R. (2015) · Diabetic Medicine · doi:10.1111/dme.12766 · Cited by 15
Self-citationLeelarathna, L., Dellweg, S., Mader, J. K., Barnard, K. D., Benesch, C., Ellmerer, M., Heinemann, L., Kojzar, H., Thabit, H., Wilinska, M. E., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006075 · Cited by 14
Self-citation
Cited by
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 737
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
“, 3–24 weeks) in the home setting.(14,18,38) Comparing our results to previous short-term studies is difficult.”
ResultChiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 509
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.